Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles
ACS Medicinal Chemistry Letters2013Vol. 4(6), pp. 551–555
Citations Over TimeTop 10% of 2013 papers
Yingcai Wang, Jiwen Liu, Paul J. Dransfield, Liusheng Zhu, Zhongyu Wang, Xiaohui Du, Xian‐Yun Jiao, Yongli Su, An‐Rong Li, Sean P. Brown, Annie Kasparian, Marc Vimolratana, Ming Yu, Vatee Pattaropong, Jonathan B. Houze, Gayathri Swaminath, Thanhvien Tran, Khanh Q. Nguyen, Qi Guo, Jane Zhang, Run Zhuang, Frank Li, Lynn Miao, Michael D. Bartberger, Tiffany L. Correll, David Chow, Simon Wong, Jian Luo, Daniel C.-H. Lin, Julio C. Medina
Abstract
GPR40 (FFAR1 or FFA1) is a target of high interest being pursued to treat type II diabetes due to its unique mechanism leading to little risk of hypoglycemia. We recently reported the discovery of AM-1638 (2), a potent full agonist of GPR40. In this report, we present the discovery of GPR40 full agonists containing conformationally constrained tricyclic spirocycles and their structure-activity relationships leading to more potent agonists such as AM-5262 (26) with improved rat PK profile and general selectivity profile. AM-5262 enhanced glucose stimulated insulin secretion (mouse and human islets) and improved glucose homeostasis in vivo (OGTT in HF/STZ mice) when compared to AM-1638.
Related Papers
- → Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules(2006)396 cited
- → GPR40: A therapeutic target for mediating insulin secretion(2012)55 cited
- → Discovery and development of a selective GPR40/FFAR1 agonist, fasiglifam, for treatment of type 2 diabetes mellitus(2014)1 cited
- → The Future of Antidiabetic Drug Development: GPR40-Selective Agonist TAK-875(2010)
- Progress in free fatty acid receptor GPR40(2005)